Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

From the basics of immunotherapies to the latest research results; from understanding different treatment options to the management of toxicities and interpretation of new data, the ESMO Immuno-Oncology Congress will cater to the diverse needs of oncology stakeholders with an interest in this topical field of cancer treatment.

ESMO Immuno-Oncology 2022

ESMO Immuno-Oncology 2022
07–09 December 2022 | Geneva, Switzerland

ESMO Immuno-Oncology 2022

ESMO Immuno-Oncology 2022
07–09 December 2022 | Geneva, Switzerland
From the basics of immunotherapies to the latest research results; from understanding different treatment options to the management of toxicities and interpretation of new data, the ESMO Immuno-Oncology Congress will cater to the diverse needs of oncology stakeholders with an interest in this topical field of cancer treatment.
Assessing the role of PARP inhibitors and immunotherapy in ovarian cancer 2:38
Assessing the role of PARP inhibitors and immunotherapy in ovarian cancer
Anniina Färkkilä • 14 Dec 2022
Breast and gynecological cancer highlights at ESMO Immuno-Oncology 2022 1:02
Breast and gynecological cancer highlights at ESMO Immuno-Oncology 2022
Anniina Färkkilä • 14 Dec 2022
Overcoming resistance to PARP inhibition in ovarian cancer 1:22
Overcoming resistance to PARP inhibition in ovarian cancer
Anniina Färkkilä • 14 Dec 2022
What does the future hold for LAG-3 as a novel target in melanoma? 0:49
What does the future hold for LAG-3 as a novel target in melanoma?
Omid Hamid • 29 Nov 2022
Addressing and overcoming limitations in cancer vaccines 2:31
Addressing and overcoming limitations in cancer vaccines
Michael Nishimura • 28 Nov 2022
Omitting total lymph node dissection and adjuvant therapy in melanoma 2:12
Omitting total lymph node dissection and adjuvant therapy in melanoma
Irene Reijers • 30 Nov 2022
PRADO: personalized response-driven therapy in resectable stage III melanoma 2:24
PRADO: personalized response-driven therapy in resectable stage III melanoma
Irene Reijers • 30 Nov 2022
Fianlimab and cemiplimab in patients with advanced melanoma 8:43
Fianlimab and cemiplimab in patients with advanced melanoma
Omid Hamid • 29 Nov 2022
Optimizing TILs as a novel immunotherapy strategy in metastatic melanoma 1:04
Optimizing TILs as a novel immunotherapy strategy in metastatic melanoma
Maartje Rohaan • 29 Nov 2022
The content of VJOncology is intended for healthcare professionals